Quanterix

Quanterix experts Milena Dumont Milutinovic, Mirella El Khoury, & Susana Rodriguez-Vilariño, PhD., recently attended IRCI 2025 in Lyon, France. It was a great opportunity to share our innovations, connect with experts, and be part of shaping the future of immune-based research.

📍We’ve landed at AAIC 2025! Come find us at Booth #1510 for a photo-op with our life-size microtubule. #AAIC2025 #alzheimersdisease

Want to explore how p-Tau 205 offers unique insights into late-stage tau pathology? Our quick-reference fact sheet highlights p-Tau 205’s role in tracking NFT formation and disease progression—independent of amyloid pathology. Download now: quanterix.com/whitepapers-ap…

AAIC® is this Sunday, are you ready? Visit us at our booth #1510 to experience interactive demos of our latest biomarker detection instruments, a photo op with our giant TAU display, prize giveaways, and more: quanterix.com/conferences/al… #AlzheimersDisease #AlzheimersResearch

79% of scientists and researchers recently polled believe that p-tau 217 holds the most promise for advancing early detection of AD in the next 5 years. Learn how we're advancing AD pathology detection with the Simoa® ALZpath p-Tau217 Assay: quanterix.com/advancing-alzh…

The brain-derived tau (BD-Tau) assay was recently evaluated in this multi-cohort study as a potential biomarker of treatment effect in AD and FTD patients receiving an anti-tau drug. Learn more: alz-journals.onlinelibrary.wiley.com/doi/full/10.10…

The Simoa® IL-12 p70 Advantage PLUS Assay enables femtogram-level detection on the HD-X system, providing high-resolution, reproducible immune data. Learn more: quanterix.com/simoa-assay-ki…

AAIC® is just a few weeks away! Visit us at our booth #1510 to experience interactive demos of our latest biomarker detection instruments, a photo op with our giant TAU display, prize giveaways, and more: quanterix.com/conferences/al… #AlzheimersDisease #AlzheimersResearch

Tau, a key protein in neurodegenerative diseases, remains a critical biomarker in understanding AD. Recent advancements in Tau biomarker research are breaking new ground in early diagnosis, prognosis, and treatment monitoring. Learn more: quanterix.com/whitepapers-ap…

Recent preclinical studies continue to demonstrate the utility of Simoa® #biomarkers in animal models of #neurodegeneration. Aeran et al.: lnkd.in/eE2-BMQP Mckean et al.: lnkd.in/exc2bhTV

Attending AAIC 2025? Let’s connect and explore how we can support your research. Learn more: bit.ly/3Gsdm6x #AAIC2025 #alzheimersdisease #biomarkers

Quanterix experts Diana Caracino and Adam Shepro recently attended ELRIG’s USA Forum on #Neuroimmunology in Drug Discovery in Boston, MA, which highlighted the latest advancements in understanding the role of neuroimmune cells in neurological diseases.

We’re thrilled to welcome Akoya Biosciences to the Quanterix Family. Read our latest press release to learn more about our acquisition of Akoya Biosciences and what it means for the future: bit.ly/3Grnht4

A new 6-year follow-up study highlights how plasma #biomarkers measured using Simoa® assays—including NfL, GFAP, and key hashtag#cytokines—can track disease activity, relapse, and response to immunotherapy in LGI1 autoimmune encephalitis. Learn more: frontiersin.org/journals/neuro…

#AAIC Are you ready for the Alzheimer’s Association International Conference® this month? RSVP ahead of time for our daily open house to recharge, connect with the team, and enjoy lunch on us! 👉 quanterix.com/conferences/al… #AlzheimersDisease #AlzheimersResearch

How do pTau 205 and pTau 212 differ biochemically and pathologically from pTau 181 or pTau 217? Learn how in the most recent episode of 2 Minutes with Q with Kishore Malyavantham, Ph.D., Vice President of Research and Development with Quanterix.

Many people suffer head injuries, but the real damage often goes unnoticed. Now, thanks to advances in blood-based biomarker tech, scientists can detect subtle brain changes after trauma—bringing hope for earlier diagnosis & better outcomes. Learn more: bit.ly/4leNSc2

#News Can a Drop of Blood Reveal Cognitive Decline in #Parkinson’s Disease? A new review highlights recent breakthroughs in #biomarker research doing just that. Read the full review: bit.ly/3TLYF0Z

We're nearly one month away from the Alzheimer’s Association International Conference®! RSVP ahead of time for our daily open house to recharge, connect with the team, and enjoy lunch on us! 👉 quanterix.com/conferences/al… #AlzheimersDisease #AlzheimersResearch

Quanterix's two new ultrasensitive Simoa® assays, pTau205 & pTau212, are advancing alzheimer's disease detection. Learn more the power of these assays in our latest publication brief: quanterix.com/whitepapers-ap… #Alzheimers #Biomarkers #Neuroscience #Neurodegeneration